Broad and Cross-Clade CD4+ T-Cell Responses Elicited by a DNA Vaccine Encoding Highly Conserved and Promiscuous HIV-1 M-Group Consensus Peptides

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Almeida, Rafael Ribeiro ^a   Rosa, Daniela Santoro ^a,b,c   Ribeiro, Susan Pereira ^a,b   Santana, Vinicius Canato ^a   Kallás, Esper Georges ^a   Sidney, John ^d   Sette, Alessandro ^d   Kalil, Jorge ^a,b   Cunha Neto, Edecio ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Institute for Investigation in Immunology INCT   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GAG PROTEIN; GAMMA INTERFERON; HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; NEF PROTEIN; PEPTIDE; POL PROTEIN; REV PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VIF PROTEIN; VPR PROTEIN; VPU PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN RECOGNITION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONSENSUS SEQUENCE; CONTROLLED STUDY; CYTOKINE RELEASE; DNA IMMUNIZATION; DRUG DESIGN; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL;

AIDS VACCINES; ALGORITHMS; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CONSENSUS SEQUENCE; CROSS REACTIONS; EPITOPES; EPITOPES, T-LYMPHOCYTE; FEMALE; HIV INFECTIONS; HIV-1; HLA ANTIGENS; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; IMMUNIZATION; INTERFERON-GAMMA; MICE; PEPTIDES; PROTEIN BINDING; TUMOR NECROSIS FACTOR-ALPHA; VACCINES, DNA;

HUMAN IMMUNODEFICIENCY VIRUS 1; MURINAE; MUS;

EID: 84866503033     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045267     Document Type: Article

References (72)

1. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, et al. (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372: 1881-1893.
2. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. New England Journal of Medicine 361: 2209-2220.
3. McElrath MJ, Haynes BF, (2010) Induction of Immunity to Human Immunodeficiency Virus Type-1 by Vaccination. Immunity 33: 542-554.
4. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, et al. (2011) Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473: 523-U270.
5. Corey L, McElrath MJ, Kublin JG, (2009) Post-Step modifications for research on HIV vaccines. Aids 23: 3-8.
6. Wilson NA, Keele BF, Reed JS, Piaskowski SM, MacNair CE, et al. (2009) Vaccine-Induced Cellular Responses Control Simian Immunodeficiency Virus Replication after Heterologous Challenge. Journal of Virology 83: 6508-6521.
7. Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC, et al. (2009) Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nature Medicine 15: 293-299.
8. Hel Z, Tsai WP, Tryniszewska E, Nacsa J, Markham PD, et al. (2006) Improved vaccine protection from simian AIDS by the addition of nonstructural simian immunodeficiency virus genes. Journal of Immunology 176: 85-96.
9. Liu JY, O'Brien KL, Lynch DM, Simmons NL, La Porte A, et al. (2009) Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457: 87-91.
10. Wilson CC, McKinney D, Anders M, MaWhinney S, Forster J, et al. (2003) Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to multiple conserved epitopes in HIV-1. Journal of Immunology 171: 5611-5623.
11. Barouch DH, Santra S, Schmitz JE, Kuroda MJ, Fu TM, et al. (2000) Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290: 486-492.
12. Egan MA, Charini WA, Kuroda MJ, Schmitz JE, Racz P, et al. (2000) Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection. Journal of Virology 74: 7485-7495.
13. Porichis F, Kaufmann DE, (2011) HIV-specific CD4 T cells and immune control of viral replication. Current Opinion in Hiv and Aids 6: 174-180.
14. Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, et al. (2002) HIV preferentially infects HIV-specific CD4(+) T cells. Nature 417: 95-98.
15. Gloster SE, Newton P, Cornforth D, Lifson JD, Williams I, et al. (2004) Association of strong virus-specific CD4 T cell responses with efficient natural control of primary HIV-1 infection. Aids 18: 749-755.
16. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, et al. (1997) Vigorous HIV-1-specific CD4(+) T cell responses associated with control of viremia. Science 278: 1447-1450.
17. Zheng N, Fujiwara M, Ueno T, Oka S, Takiguchi M, (2009) Strong Ability of Nef-Specific CD4(+) Cytotoxic T Cells To Suppress Human Immunodeficiency Virus Type 1 (HIV-1) Replication in HIV-1-Infected CD4(+) T Cells and Macrophages. Journal of Virology 83: 7668-7677.
18. Sacha JB, Giraldo-Vela JP, Buechler MB, Martins MA, Maness NJ, et al. (2009) Gag- and Nef-specific CD4(+) T cells recognize and inhibit SIV replication in infected macrophages early after infection. Proceedings of the National Academy of Sciences of the United States of America 106: 9791-9796.
19. Vaccari M, Mattapallil J, Song K, Tsai WP, Hryniewicz A, et al. (2008) Reduced protection from simian immunodeficiency virus SIVmac251 infection afforded by memory CD8(+) T cells induced by vaccination during CD4(+) T-cell deficiency. Journal of Virology 82: 9629-9638.
20. Gauduin MC, Yu Y, Barabasz A, Carville A, Piatak M, et al. (2006) Induction of a virus-specific effector-memory CD4(+) T cell response by attenuated SIV infection. Journal of Experimental Medicine 203: 2661-2672.
21. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, et al. (2002) AIDS- Diversity considerations in HIV-1 vaccine selection. Science 296: 2354-2360.
22. Rolland M, Nickle DC, Mullins JI, (2007) HIV-1 group M conserved elements vaccine. Plos Pathogens 3: 1551-1555.
23. Weaver EA, Lu ZJ, Camacho ZT, Moukdar F, Liao HX, et al. (2006) Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group M consensus env immunogen. Journal of Virology 80: 6745-6756.
24. Santra S, Korber BT, Muldoon M, Barouch DH, Nabel GJ, et al. (2008) A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys. Proceedings of the National Academy of Sciences of the United States of America 105: 10489-10494.
25. Depla E, Van der Aa A, Livingston BD, Crimi C, Allosery K, et al. (2008) Rational design of a multiepitope vaccine encoding T-Lymphocyte epitopes for treatment of chronic hepatitis B virus infections. Journal of Virology 82: 435-450.
26. Kovjazin R, Volovitz I, Kundel Y, Rosenbaum E, Medalia G, et al. (2011) ImMucin: A novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors. Vaccine 29: 4676-4686.
27. Depil S, Morales O, Castelli FA, Delhem N, Francois V, et al. (2007) Determination of a HLA II promiscuous peptide cocktail as potential vaccine against EBV latency II malignancies. Journal of Immunotherapy 30: 215-226.
28. Martins MA, Wilson NA, Reed JS, Ahn CD, Klimentidis YC, et al. (2010) T-Cell Correlates of Vaccine Efficacy after a Heterologous Simian Immunodeficiency Virus Challenge. Journal of Virology 84: 4352-4365.
29. Staprans SI, Barry AP, Silvestri G, Safrit JT, Kozyr N, et al. (2004) Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. Proceedings of the National Academy of Sciences of the United States of America 101: 13026-13031.
30. Pettersen FO, Tasken K, Kvale D, (2010) Combined Env- and Gag-specific T cell responses in relation to programmed death-1 receptor and CD4+T cell loss rates in human immunodeficiency virus-1 infection. Clinical and Experimental Immunology 161: 315-323.
31. Ranasinghe S, Flanders M, Cutler S, Soghoian DZ, Ghebremichael M, et al. (2012) HIV-Specific CD4 T Cell Responses to Different Viral Proteins Have Discordant Associations with Viral Load and Clinical Outcome. Journal of Virology 86: 277-283.
32. Ribeiro SP, Rosa DS, Fonseca SG, Mairena EC, Postol E, et al. (2010) A Vaccine Encoding Conserved Promiscuous HIV CD4 Epitopes Induces Broad T Cell Responses in Mice Transgenic to Multiple Common HLA Class II Molecules. Plos One 5.
33. Rosa DS, Ribeiro SP, Almeida RR, Mairena EC, Postol E, et al. (2011) A DNA Vaccine Encoding Multiple HIV CD4 Epitopes Elicits Vigorous Polyfunctional, Long-Lived CD4(+) and CD8(+) T Cell Responses. Plos One 6.
34. Sturniolo T, Bono E, Ding JY, Raddrizzani L, Tuereci O, et al. (1999) Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nature Biotechnology 17: 555-561.
35. Schroers R, Huang XF, Hammer J, Zhang JW, Chen SY, (2002) Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+T-helper cells. Cancer Research 62: 2600-2605.
36. de Lalla C, Sturniolo T, Abbruzzese L, Hammer J, Sidoli A, et al. (1999) Cutting edge: Identification of novel T cell epitopes in Lol p5a by computational prediction. Journal of Immunology 163: 1725-1729.
37. Rosa DS, Iwai LK, Tzelepis F, Bargieri DY, Medeiros MA, et al. (2006) Immunogenicity of a recombinant protein containing the Plasmodium vivax vaccine candidate MSP1(19) and two human CD4(+) T-cell epitopes administered to non-human primates (Callithrix jacchus jacchus). Microbes and Infection 8: 2130-2137.
38. Iwai LK, Yoshida M, Sadahiro A, da Silva WR, Marin ML, et al. (2007) T-cell recognition of Paracoccidioides brasiliensis gp43-derived peptides in patients with paracoccidioidomycosis and healthy individuals. Clinical and Vaccine Immunology 14: 474-476.
39. Bian HJ, Hammer J, (2004) Discovery of promiscuous HLA-II-restricted T cell epitopes with TEPITOPE. Methods 34: 468-475.
40. Iwai LK, Yoshida M, Sidney J, Shikanai-Yasuda MA, Goldberg AC, et al. (2003) In silico prediction of peptides binding to multiple HLA-DR molecules accurately identifies immunodominant epitopes from gp43 of Paracoccidioides brasiliensis frequently recognized in primary peripheral blood mononuclear cell responses from sensitized individuals. Molecular Medicine 9: 209-219.
41. Sidney J, Southwood S, Oseroff C, del Guercio MF, Sette A, et al. (2001) Measurement of MHC/peptide interactions by gel filtration. Current protocols in immunology Chapter 18: Unit 18.3.
42. Livingston B, Crimi C, Newman M, Higashimoto Y, Appella E, et al. (2002) A rational strategy to design multiepitope immunogens based on multiple th lymphocyte epitopes. Journal of Immunology 168: 5499-5506.
43. Batista MD, Ferreira S, Sauer MM, Tomiyama H, Maidana Giret MT, et al. (2009) High Human Herpesvirus 8 (HHV-8) Prevalence, Clinical Correlates and High Incidence among Recently HIV-1-Infected Subjects in Sao Paulo, Brazil. Plos One 4.
44. Kallas EG, Bassichetto KC, Oliveira (2004) Establishment of the serologic testing algorithm for recent human immunodeficiency virus (HIV) seroconversion (STARHS) strategy in the city of São Paulo, Brazil. The Brazilian Journal of Infectious Diseases 8: 8.
45. Sa-Filho D, Kallas EG, Sanabani S, Sabino E, Sucupira MC, et al. (2007) Characterization of the full-length human immunodeficiency virus-1 genome from recently infected subjects in Brazil. Aids Research and Human Retroviruses 23: 1087-1094.
46. Sanabani SS, de Souza Pastena ER, da Costa AC, Martinez VP, Kleine-Neto W, et al. (2011) Characterization of Partial and Near Full-Length Genomes of HIV-1 Strains Sampled from Recently Infected Individuals in Sao Paulo, Brazil. Plos One 6.
47. Samri A, Durier C, Urrutia A, Sanchez I, Gahery-Segard H, et al. (2006) Evaluation of the interlaboratory concordance in quantification of human immunodeficiency virus-specific T cells with a gamma interferon enzyme-linked immunospot assay. Clinical and Vaccine Immunology 13: 684-697.
48. Quah BJC, Warren HS, Parish CR, (2007) Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester. Nature Protocols 2: 2049-2056.
49. Lacap PA, Huntington JD, Luo M, Nagelkerke NJD, Bielawny T, et al. (2008) Associations of human leukocyte antigen DRB with resistance or susceptibility to HIV-1 infection in the Pumwani Sex Worker Cohort. Aids 22: 1029-1038.
50. Ferre AL, Hunt PW, McConnell DH, Morris MM, Garcia JC, et al. (2010) HIV Controllers with HLA-DRB1*13 and HLA-DQB1*06 Alleles Have Strong, Polyfunctional Mucosal CD4(+) T-Cell Responses. Journal of Virology 84: 11020-11029.
51. Fonseca SG, Coutinho-Silva A, Fonseca LAM, Segurado AC, Moraes SL, et al. (2006) Identification of novel consensus CD4 T-cell epitopes from clade B HIV-1 whole genome that are frequently recognized by HIV-1 infected patients. Aids 20: 2263-2273.
52. Bansal A, Gough E, Ritter D, Wilson C, Mulenga J, et al. (2006) Group M-based HIV-1 Gag peptides are frequently targeted by T cells in chronically infected US and Zambian patients. Aids 20: 353-360.
53. Bijker MS, van den Eeden SJF, Franken KL, Melief CJM, Offringa R, et al. (2007) CD8(+) CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. Journal of Immunology 179: 5033-5040.
54. Zhang GL, Srinivasan KN, Veeramani A, August JT, Brusic V, (2005) PREDBALB/c: a system for the prediction of peptide binding to H2(d) molecules, a haplotype of the BALB/c mouse. Nucleic Acids Research 33: W180-W183.
55. BenMohamed L, Bertrand G, McNamara CD, Gras-Masse H, Hammer J, et al. (2003) Identification of novel immunodominant CD4(+) Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity. Journal of Virology 77: 9463-9473.
56. Liao H-X, Sutherland LL, Xia S-M, Brock ME, Scearce RM, et al. (2006) A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and CHIV-1 primary viruses. Virology 353: 268-282.
57. Suhrbier A, (2002) Polytope vaccines for the codelivery of multiple CD8T-cell epitopes. Expert Review of Vaccines 1: 207-213.
58. Ishioka GY, Fikes J, Hermanson G, Livingston B, Crimi C, et al. (1999) Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes. Journal of Immunology 162: 3915-3925.
59. Fuller DH, Shipley T, Allen TM, Fuller JT, Wu MS, et al. (2007) Immunogenicity of hybrid DNA vaccines expressing hepatitis B core particles carrying human and simian immunodeficiency virus epitopes in mice and rhesus macaques. Virology 364: 245-255.
60. Ngumbela KC, Day CL, Mncube Z, Nair K, Ramduth D, et al. (2008) Targeting of a CD8 T cell Env epitope presented by HLA-B*5802 is associated with markers of HIV disease progression and lack of selection pressure. Aids Research and Human Retroviruses 24: 72-82.
61. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, et al. (2007) CD8(+) T-cell responses to different HIV proteins have discordant associations with viral load. Nature Medicine 13: 46-53.
62. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, et al. (2012) Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial. New England Journal of Medicine 366.
63. Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, et al. (2012) Extended Follow-up Confirms Early Vaccine-Enhanced Risk of HIV Acquisition and Demonstrates Waning Effect Over Time Among Participants in a Randomized Trial of Recombinant Adenovirus HIV Vaccine (Step Study). Journal of Infectious Diseases 206.
64. Barouch DH, O'Brien KL, Simmons NL, King SL, Abbink P, et al. (2010) Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nature Medicine 16: 319-U116.
65. Letourneau S, Im EJ, Mashishi T, Brereton C, Bridgeman A, et al. (2007) Design and Pre-Clinical Evaluation of a Universal HIV-1 Vaccine. Plos One 2.
66. Chevalier MF, Juelg B, Pyo A, Flanders M, Ranasinghe S, et al. (2011) HIV-1-Specific Interleukin-21(+) CD4(+) T Cell Responses Contribute to Durable Viral Control through the Modulation of HIV-Specific CD8(+) T Cell Function. Journal of Virology 85: 733-741.
67. Nakanishi Y, Lu B, Gerard C, Iwasaki A, (2009) CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature 462: 510-U205.
68. Shedlock DJ, Shen H, (2003) Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300: 337-339.
69. Almeida JR, Price DA, Papagno L, Arkoub ZA, Sauce D, et al. (2007) Superior control of HIV-1 replication by CD8(+) T cells is reflected by their avidity, polyfunctionality, and clonal turnover. Journal of Experimental Medicine 204: 2473-2485.
70. Boaz MJ, Waters A, Murad S, Easterbrook PJ, Vyakarnam A, (2002) Presence of HIV-1 gag-specific IFN-gamma+IL-2(+) and CD28(+)IL-2(+) CD4 T cell responses is associated with nonprogression in HIV-1 infection. Journal of Immunology 169: 6376-6385.
71. Emu B, Sinclair E, Favre D, Moretto WJ, Hsue P, et al. (2005) Phenotypic, functional, and kinetic parameters associated with a apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. Journal of Virology 79: 14169-14178.
72. Sui YJ, Zhu Q, Gagnon S, Dzutsev A, Terabe M, et al. (2010) Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques. Proceedings of the National Academy of Sciences of the United States of America 107: 9843-9848.